Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction
Eric J Velazquez, Kerry L Lee, Marek A Deja, Anil Jain, George Sopko, Andrey Marchenko, Imtiaz S Ali, Gerald Pohost, Sinisa Gradinac, William T Abraham, Michael Yii, Dorairaj Prabhakaran, Hanna Szwed, Paolo Ferrazzi, Mark C Petrie, Christopher M O'Connor, Pradit Panchavinnin, Lilin She, Robert O Bonow, Gena Roush Rankin Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2011
BACKGROUND: The role of coronary-artery bypass grafting (CABG) in the treatment of patients with coronary artery disease and heart failure has not been clearly established. METHODS: Between July 2002 and May 2007, a total of 1212 patients with an ejection fraction of 35% or less and coronary artery disease amenable to CABG were randomly assigned to medical therapy alone (602 patients) or medical therapy plus CABG (610 patients). The primary outcome was the rate of death from any cause. Major secondary outcomes included the rates of death from cardiovascular causes and of death from any cause or hospitalization for cardiovascular causes. RESULTS: The primary outcome occurred in 244 patients (..View full abstract
Awarded by National Heart, Lung, and Blood Institute
Awarded by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
Supported by grants (U01HL69015 and U01HL69013) from the National Heart, Lung, and Blood Institute and by Abbott Laboratories.Dr. Velazquez reports receiving consulting fees from Novartis, Gilead, and Boehringer Ingelheim Pharmaceuticals; Dr. Abraham, consulting fees from Medtronic, St. Jude Medical, Biotronik, and CardioMEMS; and Dr. Rouleau, consulting fees and grant support from Novartis. No other potential conflict of interest relevant to this article was reported.